Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$8.39
+10.5%
$8.04
$5.20
$10.67
$1.13B1.161.38 million shs2.58 million shs
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$78.83
+0.3%
$84.07
$64.94
$90.04
$3.90B0.43307,687 shs417,026 shs
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$23.17
0.0%
$25.02
$11.16
$27.64
$1.07B0.48906,977 shs515,308 shs
Principia Biopharma Inc. stock logo
PRNB
Principia Biopharma
$100.05
$100.05
$25.35
$101.89
$3.32B0.86729,676 shsN/A
Xencor, Inc. stock logo
XNCR
Xencor
$9.33
+12.8%
$8.61
$7.16
$27.24
$664.02M0.85681,773 shs948,157 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
+1.61%+1.47%-7.33%-0.26%+34.81%
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
-0.23%-1.90%-7.47%-5.52%+15.42%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
-0.17%-0.30%-10.74%-10.29%+12.52%
Principia Biopharma Inc. stock logo
PRNB
Principia Biopharma
0.00%0.00%0.00%0.00%0.00%
Xencor, Inc. stock logo
XNCR
Xencor
+4.16%+2.48%-14.30%-6.13%-54.51%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
2.7385 of 5 stars
3.51.00.00.02.50.81.9
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
4.1912 of 5 stars
2.34.00.03.52.81.71.9
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
3.5463 of 5 stars
2.22.00.03.92.72.50.6
Principia Biopharma Inc. stock logo
PRNB
Principia Biopharma
N/AN/AN/AN/AN/AN/AN/AN/A
Xencor, Inc. stock logo
XNCR
Xencor
4.0012 of 5 stars
3.42.00.03.92.00.81.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
3.00
Buy$11.5037.07% Upside
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
2.50
Moderate Buy$93.3318.40% Upside
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
2.33
Hold$26.4414.13% Upside
Principia Biopharma Inc. stock logo
PRNB
Principia Biopharma
0.00
N/AN/AN/A
Xencor, Inc. stock logo
XNCR
Xencor
2.75
Moderate Buy$28.00200.11% Upside

Current Analyst Ratings Breakdown

Latest PCRX, AUPH, XNCR, PRNB, and PBH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/9/2025
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$32.00 ➝ $30.00
5/8/2025
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
5/8/2025
Xencor, Inc. stock logo
XNCR
Xencor
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$22.00 ➝ $6.00
4/30/2025
Xencor, Inc. stock logo
XNCR
Xencor
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$31.00
4/21/2025
Xencor, Inc. stock logo
XNCR
Xencor
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$247.30M4.58$0.35 per share24.22$2.68 per share3.13
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$1.14B3.42$5.21 per share15.14$37.04 per share2.13
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$702.77M1.53$4.31 per share5.38$16.86 per share1.37
Principia Biopharma Inc. stock logo
PRNB
Principia Biopharma
$35.16M94.50N/AN/A$10.95 per share9.14
Xencor, Inc. stock logo
XNCR
Xencor
$110.49M6.01N/AN/A$9.63 per share0.97
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$5.75M$0.2829.9614.98N/A16.11%14.27%9.93%7/30/2025 (Estimated)
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$214.60M$4.2918.3816.562.3718.86%12.87%6.78%8/6/2025 (Estimated)
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
-$99.56M-$2.28N/A9.02N/A-14.78%13.78%7.00%7/29/2025 (Estimated)
Principia Biopharma Inc. stock logo
PRNB
Principia Biopharma
-$53.79M-$2.09N/AN/AN/AN/A-23.08%-21.11%N/A
Xencor, Inc. stock logo
XNCR
Xencor
-$232.62M-$3.06N/AN/AN/A-181.17%-31.94%-22.19%8/4/2025 (Estimated)

Latest PCRX, AUPH, XNCR, PRNB, and PBH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2025Q2 2025
Xencor, Inc. stock logo
XNCR
Xencor
-$0.78N/AN/AN/A$22.59 millionN/A
7/29/2025Q2 2025
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$0.73N/AN/AN/A$183.11 millionN/A
5/12/2025Q1 2025
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$0.08$0.16+$0.08$0.16$61.06 million$62.47 million
5/8/2025Q4 2025
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$1.30$1.32+$0.02$1.00$289.36 million$296.52 million
5/8/2025Q1 2025
Xencor, Inc. stock logo
XNCR
Xencor
-$0.60-$0.66-$0.06-$0.66$23.44 million$32.73 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
N/AN/AN/AN/AN/A
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
N/AN/AN/AN/AN/A
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
N/AN/AN/AN/AN/A
Principia Biopharma Inc. stock logo
PRNB
Principia Biopharma
N/AN/AN/AN/AN/A
Xencor, Inc. stock logo
XNCR
Xencor
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
0.16
5.93
5.26
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
0.55
4.20
2.82
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
0.48
2.41
1.99
Principia Biopharma Inc. stock logo
PRNB
Principia Biopharma
N/A
17.01
17.01
Xencor, Inc. stock logo
XNCR
Xencor
0.16
5.89
5.89
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
300135.10 million118.62 millionOptionable
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
54049.42 million48.72 millionOptionable
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
72046.29 million43.33 millionOptionable
Principia Biopharma Inc. stock logo
PRNB
Principia Biopharma
6533.21 millionN/ANot Optionable
Xencor, Inc. stock logo
XNCR
Xencor
28071.17 million67.45 millionOptionable

Recent News About These Companies

Xencor Reports First Quarter 2025 Financial Results
Xencor initiated with an Outperform at William Blair
Xencor participates in a conference call with JPMorgan

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurinia Pharmaceuticals stock logo

Aurinia Pharmaceuticals NASDAQ:AUPH

$8.39 +0.80 (+10.54%)
Closing price 04:00 PM Eastern
Extended Trading
$8.12 -0.27 (-3.22%)
As of 05:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Prestige Consumer Healthcare stock logo

Prestige Consumer Healthcare NYSE:PBH

$78.83 +0.21 (+0.27%)
As of 03:56 PM Eastern

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Pacira BioSciences stock logo

Pacira BioSciences NASDAQ:PCRX

$23.17 -0.01 (-0.04%)
Closing price 04:00 PM Eastern
Extended Trading
$23.16 -0.01 (-0.02%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Principia Biopharma stock logo

Principia Biopharma NASDAQ:PRNB

Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.

Xencor stock logo

Xencor NASDAQ:XNCR

$9.33 +1.06 (+12.82%)
Closing price 04:00 PM Eastern
Extended Trading
$9.34 +0.01 (+0.05%)
As of 05:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.